Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC
Researchers randomly assigned 56 treatment-naive patients with advanced NSCLC to 3 cohorts: nivolumab plus gemcitabine and cisplatin, nivolumab plus pemetrexed and cisplatin, and nivolumab plus paclit
|The following article features coverage from the IASLC 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. Click here to read more of Cancer Therapy Advisor's conference coverage.|
A 3-year update for a trial evaluating nivolumab plus chemotherapy showed an improved overall survival (OS) and overall response rate (ORR) among patients with advanced non–small cell lung cancer (NSCLC), according to a study presented at the International Association for the Study of Lung Cancer (IASLC) 18th Annual World Conference on Lung Cancer (WCLC) in Japan.1
In the phase 1 CheckMate 012 study (ClinicalTrials.gov Identifier: NCT01454102), researchers randomly assigned 56 treatment-naive patients with advanced NSCLC to 3 cohorts: nivolumab plus gemcitabine and cisplatin, nivolumab plus pemetrexed and cisplatin, and nivolumab plus paclitaxel and carboplatin. Patients received 4 cycles of nivolumab plus chemotherapy and were then maintained on nivolumab monotherapy.
At time of analysis, the minimum follow-up period was 45.5 months. Patients had a median duration of response of 10.4 months (95% CI, 5.1-26.3) and a median progression-free survival of 6.0 months (95% CI, 4.8-8.3).
The median OS was 19.2 months (95% CI, 14.1-23.8) and the 3-year OS rate was 25%.
ORR was 46%. Patients had similar ORRs and OS rates regardless of PD-L1 expression. The ORRs were 48% and 52% in patients with <1% and >1% PD-L1 expression, respectively, and the median OS was 19.2 months (95% CI, 12.2-23.8) compared with 20.2 months (95% CI, 10.9-27.2), respectively.
Both PD-L1 subgroups had 3-year OS rates of 22%
The authors concluded that “[t]hese results support further evaluation of nivolumab-chemotherapy combinations as first-line treatment for advanced NSCLC, which are being explored in CheckMate 227 ([ClinicalTrials.gov Identifier]: NCT02477826).”
Read more of Cancer Therapy Advisor's coverage of the IASLC 18th World Conference on Lung Cancer (WCLC) by visiting the conference page.
- Juergens RJ, Hellmann MD, Brahmer JR, et al. First-line nivolumab plus platinum-based doublet chemotherapy for advanced NSCLC: CheckMate 012 3-year update. Presented at: International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer; October 2017; Yokohama, Japan. Abstract OA 17.03.